In 2023, cardiovascular system medicine sales in Canada stood at a higher baseline compared to the coming years. From 2024 through 2028, the data forecasts a consistent decline, with sales percentages dropping from 7.5% to 6% of total sales. This represents a year-on-year decline of approximately 5.3% from 2024 to 2025, with subsequent yearly declines averaging around 5.6%. The Compound Annual Growth Rate (CAGR) over these years predicts a continued downward trend, reflecting reduced market share for cardiovascular medications.
Future trends to watch for include potential impacts from advancements in alternative therapies, generic drug market fluctuations, and regulatory changes. These factors could significantly alter market dynamics, influencing the forecasted trajectories for cardiovascular medicine sales in Canada.
